Reference is made to the stock exchange announcement made by Lifecare ASA (the
"Company") on 13 June 2025 regarding the final results following expiry of the
exercise period for the Warrants issued in connection with the Rights Issue. A
total of 3,207,994 Warrants were exercised, raising gross proceeds of NOK 17.1
million.
The share capital increase pertaining to the issuance of the new shares as
results of exercise of Warrants has now been registered with the Norwegian
Register of Business Enterprises. The Company's new share capital is NOK
99,117,059.60 divided into 19,060,973 shares, each with a nominal value of NOK
5.20.
The Shares are expected to be delivered to applicants in the VPS on or about
26 June 2025, subject to timely payment having been received.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring ("CGM") systems to market.
Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor
technology is suitable for identifying and monitoring the occurrence of a wide
range of analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42
This information is subject to disclosure under the Norwegian Securities
Trading Act, ยง5-12. The information was submitted for publication at
2025-06-25 14:10 CEST.